(Q36362591)

13 August 2017

title

Photodynamic therapy and imiquimod immunotherapy for basal cell carcinomas (English)

1 reference

13 August 2017

1 reference

A F Nikkels

1

1 reference

13 August 2017

C Piérard-Franchimont

2

1 reference

13 August 2017

N Nikkels-Tassoudji

3

1 reference

13 August 2017

R Bourguignon

4

1 reference

13 August 2017

G E Piérard

5

1 reference

13 August 2017

publication date

1 September 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

60

1 reference

13 August 2017

issue

5

1 reference

13 August 2017

page(s)

227-234

1 reference

Skin cancer. Recognition and treatment

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1179%2FACB.2005.039

Cutaneous cancers in the Mosan region and Ardennes of Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2005.039

Principles of management of basal and squamous cell carcinoma of the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2005.039

Basal cell carcinoma: treatment options and prognosis, a scientific approach to a common malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2005.039

The role of screening in the management of skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2005.039

Awareness, knowledge and attitudes to basal cell carcinoma and actinic keratoses among the general public within Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2005.039

Skin cancer screening campaign in the German speaking Community of Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2005.039

Photodynamic therapy by topical aminolevulinic acid, dimethylsulphoxide and curettage in nodular basal cell carcinoma: a one-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2005.039

Clinical efficacy of methyl aminolevulinate (Metvix®) photodynamic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2005.039

Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2005.039

Characterization of the mononuclear infiltrate in basal cell carcinoma: a predominantly T cell-mediated immune response with minor participation of Leu-7+ (natural killer) cells and Leu-14+ (B) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2005.039

Regression in basal cell carcinoma: an immunohistochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2005.039

Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2005.039

Treatment of genital warts with an immune-response modifier (imiquimod).

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2005.039

Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2005.039

Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2005.039

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2005.039

Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2005.039

Efficacy and safety of 5% imiquimod cream in treating patients with multiple superficial basal cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2005.039

Use of imiquimod for treating skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2005.039

Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2005.039

Prolonged imiquimod treatment and graft-versus-host reaction: histological mimicry in the skin infiltration pattern of the monocyte-macrophage-dendrocyte lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2005.039

Imiquimod-responsive basal cell carcinomas and factor XIIIa-enriched dendrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2005.039

21 January 2018

Identifiers

DOI

10.1179/ACB.2005.039

1 reference

13 August 2017

1 reference